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Abstract: Various estrogen analogs were synthesized and tested for 
binding to human ERα using a fluorescence polarization displacement assay. 
Binding affinity and orientation were also predicted using docking calculations. 
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Docking was able to accurately predict relative binding affinity and orientation 
for estradiol, but only if a tightly bound water molecule bridging 
Arg394/Glu353 is present. Di-hydroxyl compounds sometimes bind in two 
orientations, which are flipped in terms of relative positioning of their 
hydroxyl groups. Di-hydroxyl compounds were predicted to bind with their 
aliphatic hydroxyl group interacting with His524 in ERα. One nonsteroid-based 
dihdroxyl compound was 1000-fold specific for ERβ over ERα, and was also 
25-fold specific for agonist ERβ versus antagonist activity. Docking predictions 
suggest this specificity may be due to interaction of the aliphatic hydroxyl 
with His475 in the agonist form of ERβ, versus with Thr299 in the antagonist 
form. But, the presence of this aliphatic hydroxyl is not required in all 
compounds, since mono-hydroxyl (phenolic) compounds bind ERα with high 
affinity, via hydroxyl hydrogen bonding interactions with the ERα 
Arg394/Glu353/water triad, and van der Waals interactions with the rest of 
the molecule. 
Keywords: Estrogen receptor, Docking, Phenolic, Breast cancer, Endocrine 
disruptor 
1. Introduction 
Estrogen receptor-α (ERα) is a 595-residue, 66 kDa protein with a 
ligand binding domain of 245 residues (28 kDa). ERα, along with 
estrogen receptor-β (ERβ), belongs to the nuclear hormone family of 
intracellular receptors. It is one of the two principal receptors 
responsible for binding the endogenous estrogen, 17β-estradiol (E2), 
shown in Figure 1.1 In the nucleus, ER binds to DNA as a dimer, 
recruiting coactivators or corepressors that will result in activating or 
repressing the transcription of different genes.3 Binding of E2 activates 
the ER, regulating activity. Both ERα and ERβ forms are found in 
different tissue types. However, ERα is expressed more in breast tissue 
and is also known to be involved in the pathway that regulates breast 
cancer development.2,4 ERα antagonists such as raloxifene (Fig. 1) can 
bind to ER in the same ligand-binding domain as E2, and disrupt 
normal ER cellular function.4,5 
 
Figure 1 Structures of 17β-estradiol and raloxifene. 
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A key structural feature of E2 is the presence of two hydroxyl 
groups that are separated by 11 Å, which permits interaction with 
conserved binding site residues Arg394/Glu353 and His 524. But, the 
receptor is capable of binding many other compounds whose 
structures resemble that of the E2 hormone.6 Some of these 
compounds are endogeneous, such as estrone and other human 
estrogens; and, some are exogeneous, like the drugs raloxifene (Fig. 
1) or tamoxifen that are used to treat breast cancer and osteoporosis.7 
In addition to drugs, there exist other exogeneous compounds, some 
naturally occurring like phytoestrogens and some synthetic such as 
organochlorines, that have measurable estrogenic activity.5 Many of 
these latter compounds have been shown to be linked to breast cancer 
as well as birth defects.8,9 Through the National Institutes of 
Environmental Health Sciences, the BSB (Biomolecular Screening 
Branch), and other federal agencies, the government has developed a 
program to test many of the chemicals currently in our environment, 
to see if they have estrogenic activity.10 
Because of the estrogen receptor’s prominent role as a breast 
cancer drug target, along with the threat posed by the potentially large 
number of estrogen agonists and antagonists in our environment (e.g., 
endocrine disruptors), it is essential to gain a better understanding of 
the binding requirements of the ERα ligand pocket. This understanding 
will allow for the design of better breast cancer drugs that interfere 
with the carcinogenic activity of estrogen agonists, and improve our 
ability to predict which pollutants might bind to ERα. Such predictions 
are strengthened by a better definition of the molecular features that 
trigger agonist or antagonist effects, as well as a validation of the 
docking methods used to predict binding. 
One technique that can provide a quick and reliable 
experimental measurement of binding affinity is fluorescence 
polarization.11 A fluorescence polarization displacement assay can be 
used to screen non-fluorescent molecules, by displacing a fluorescent 
probe with the molecule of interest.12 Such fluorescence polarization 
displacement assays have been developed previously for ERα and ERβ, 
based on a fluorescein isothiocyanate (FITC)-tagged estradiol (F-
E2).13,14 One such assay is available from Invitrogen.15 Subsequent 
studies in our lab improved the synthesis of F-E2 and examined the in 
vivo behavior of F-E2 in vivo, in fish. F-E2 was found to localize in cells 
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that develop into reproductive organs, consistent with the proposed 
role of E2 in gender determination in fish.16 An analogous fluorescence 
polarization method was developed using an intrinsically fluorescent 
nonsteroid estrogen.17 
Herein we present the synthesis of a series of phenolic mono-
and di-hydroxyl estrogen analogs, which were tested for binding 
affinity for human ERα, using a fluorescence polarization displacement 
assay based on F-E2. Estrogen (E2) is a phenolic compound comprised 
of a steroid core and a second hydroxyl group that is 11 Å from the 
phenolic hydroxyl. Compounds synthesized herein have the phenolic 
core, but vary in terms of whether they: (a) are steroid-based, and (b) 
possess a second hydroxyl group, ~11 Å from the phenol. In addition 
to binding affinity measurements for compounds, docking calculations 
were performed. Docking is the process of positioning a ligand into the 
binding site of a protein and calculating a binding energy for each 
pose.18 It has become an important early-stage method for finding 
molecules likely to bind to a protein, allowing for many chemicals to be 
rapidly screened as potential drug leads.18–20 Docking has also proven 
useful for identifying compounds as targets for pollutant remediation.21 
Besides predicting relative binding affinity, docking is used to predict 
the orientation or pose of a known ligand bound to a protein.22 
Comparison of docking predictions with experimental affinity 
measurements allows one to rationalize binding site requirements, and 
also provides validation of the predictive ability of the docking 
calculations for a given target (e.g., ERα) and class of compounds 
(phenolic mono- and di-hydroxyl compounds). This is important 
because such experimental validation provides greater confidence in 
the docking calculations when they are done on larger sets of 
compounds, where experimental verification might not be feasible. 
2. Results and discussion 
2.1. Synthesis 
Wittig olefination of estrone benzyl ether,23 followed by 
epoxidation with mCPBA gave the known24 epoxide 1 as a mixture of 
diastereomers (Scheme 1). Deprotonation of 1 with lithium 
diisopropylamine, followed by cleavage of the benzyl ether under 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Bioorganic & Medicinal Chemistry, Vol. 22, No. 1 (January 1, 2014): pg. 303-310. DOI. This article is © Elsevier and 
permission has been granted for this version to appear in e-Publications@Marquette. Elsevier does not grant permission 
for this article to be further copied/distributed or hosted elsewhere without the express permission from Elsevier. 
6 
 
dissolving metal conditions gave the allylic alcohol 2. Palladium 
catalyzed alkoxycarbonylation of the vinyl triflate derived from estrone 
benzyl ether, according to the literature procedure,25 gave n-propyl 
(20S)-3-(phenylmethoxy)-estra-1,3,5(10),16-tetraene- 17-carboxylate 
(3), which upon reduction in the presence of Raney-Ni gave the 
saturated ester 4. The skipped diene (20S)-3- (phenylmethoxy)-
19,24-dinorchola-1,3,5(10),16,22-pentaene (5) was prepared by the 
literature procedure.25 Hydrogenation of the less substituted olefin in 
the presence of Wilkinson’s catalyst, followed by debenzylation gave 7. 
Hydroboration–oxidation of 5, by the literature procedure26 gave 
(20S)-3-(phenylmethoxy)-19,24- dinorchola-1,3,5(10),16-tetraen-23-
ol (8). Subjecting 8 to acid resulted in the spirocyclic tetrahydrofuran 
9 in quantitative yield, which upon catalytic hydrogenolysis gave 10. 
Alternatively, debenzylation of 8 afforded 11. Oxidation of 11 gave 
the aldehyde 12. Reaction of 12 with an excess of methyl Grignard, 
followed by work-up with saturated aqueous ammonium chloride 
proceeded by cyclization to afford the spirocyclic tetrahydrofuran 13 
as a mixture of diastereomers. 
 
Scheme 1 Preparation of tetra- and pentacyclic ER analogs (ADD = 1,1′-
(azodicarbonyl)dipiperidine). 
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A series of p-substituted phenols were also prepared (Scheme 
2). Reduction of 4-(4′-hydroxyphenyl)cyclohexanone gave a separable 
mixture of trans-4-(4′-hydroxy-cyclohexyl)phenol 15 (86%) and its 
cis- diastereomer 14 (10%). The stereochemical assignments for each 
were made by comparison to their literature spectral data.27 Reaction 
of 4-(4′-hydroxyphenyl)cyclohexanone with hydroxylamine- 
hydrochloride gave the oxime 16. [4-((4′-Hydroxyphenyl) cyclohepta-
2,6-dienyl)methanol 17 was prepared from p-acetoxystyrene 
according to the literature procedure.28 This involved cross metathesis 
with (1-methoxycarbonyl-2-vinyl-3-pentene- 1,5-diyl)Fe(CO)3 (21), 
followed by oxidatively induced reductive elimination. Reduction of the 
resultant cyclopropane-carboxylate and concomitant Cope [3,3]-
rearrangement gave the cycloheptadiene 17. Catalytic reduction of 17 
gave the saturated cycloheptane 18. Finally, Heck-type coupling of 
methyl 5-bromo- 2-furanoate with p-acetoxystyrene gave the trans-
styrylfuranoate 19, which upon reduction with lithium aluminum 
hydride gave the furfuryl alcohol 20. 
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Scheme 2 Preparation pf p-substituted phenols. Reagents and conditions: (a) 
21,Grubbs 1st generation catalyst; (b) H2O2/NaOH; (c) LiAIH4, then 160 °C; (d) H2, 
20% Pd/C, MeOH; (e) LiAIH4, Et2 O. (See above-mentioned reference for further 
information.) 
2.2. Fluorescence polarization displacement and cell-
based ERα and ERβ luminescence activity assays 
Twelve compounds from Schemes 1 and and 2 were screened 
using fluorescence polarization, for their ability to bind ERα (Table 1). 
Only six compounds showed any significant affinity for the receptor at 
concentrations as high as 1 μM. These compounds include five of the 
six steroid-core compounds—2, 4, 7, 11, and 13—and one bicyclic 
compound—18. Of the remaining six compounds which did not bind to 
ERα, one has the steroid core while the others contain the linked ring 
cores containing a flanking hydroxyl group—a structure whose 
hydrophobic interior and hydrophilic exterior resembles that of 
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estrogen itself. The highest affinity ERα ligand was 2, with a Kd (32 
nM) approaching that of E2 (3 nM). 18 is the only non-steroid core 
compound with measurable ERα binding affinity, but an accurate Kd 
could not be obtained (estimated to be >1 μM). 
Table 1 Dissociation constants (Kd) from the fluorescence polarization displacement 
assay and IC50 data from cell-based ERα and ERβ agonist assays and ERβ antagonist 
assays 
 
Compound ERα Kd 
(nM) 
ERα agonist 
IC50 (nM) 
ERβ agonist 
IC50 (nM) 
ERβ 
antagonist 
IC50 (nM) 
E2 315 1.327 46 pM27 NA 
11 320 ± 40 NA 108 ± 67 275 ± 40 
4 320 ± 40 92 ± 1 9.8 ± 2 NA 
7 160 ± 10 NA 88 ± 9 70 ± 15 
13 160 ± 10 484 ± 1 111 ± 26 NA 
2 32 ± 5 145 ± 1 6.8 ± 0.2 NA 
18 >1 μM NA 5.4 ± 0.3 137 ± 100 
ERα antagonist behavior was not observed. NA indicates data was not of sufficient 
quality to measure activity. Assay data for E2 binding to ERα,15 and ERα agonist and 
ERβ agonist and antagonist activity in cellular assays,27 were previously reported. 
Cell-based ERα and ERβ luminescence assays were performed to 
determine whether the ERα ligands were acting as agonists or 
antagonists, and whether they had specificity for the α isoform (Table 
1, Fig. S1–6). Three compounds, 4, 13, and 2, showed agonist activity 
in the ERα assay; and, all six compounds showed ERβ agonist activity, 
with 4, 2, and 18 being the most potent; 18 is unique in its selectivity 
for ERβ over ERα, and is 25-fold more potent as an agonist, versus 
antagonist. 11, 7, and 18 displayed ERβ antagonist activity, with 7 
being the most potent. 
2.3. Docking 
Compounds were computationally docked into human ERα and 
ERβ in agonist and antagonist conformations. Poses for ERα are shown 
in Fig. S7–8. Initial control docking studies were performed with E2, to 
validate the docking method by demonstrating an ability to reproduce 
the known binding mode from the crystal structure. Interestingly, E2 
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docked with similar predicted affinity in two distinct poses for the ERα 
agonist conformation (Fig. S9, Table S1), essentially flipping the 
positioning of the two hydroxyl groups with regard to interactions with 
Arg394/Glu353 and His524, located on opposite sides of the pocket. 
The predicted pose with the phenolic hydroxyl near Arg394/Glu353 is 
referred to as the ‘normal’ mode, and that with the phenolic hydroxyl 
near His524 as the ‘reversed’ mode. But, if docking is performed on 
receptor that has the tightly bound water present near Arg394/Glu353, 
then only the expected pose is obtained; and, E2 is the ligand with 
highest predicted affinity (Table 2), as expected. Thus, all docking was 
performed with the Arg394/Glu353 water present. This binding mode 
has been studied previously using molecular dynamics, and illustrates 
the important role of active site water molecules in ligand binding.30 
Table 2 Docking of compounds prepared in Schemes 1 and and22 into the agonist 
and antagonist conformations of ERα and ERβ 
 
Compound Docking 
score for 
ERα agonist 
(kcal mol−1) 
Docking score 
for ERα 
antagonist 
(kcal mol−1) 
Docking 
score for 
ERβ agonist 
(kcal mol−1) 
Docking score 
for ERβ 
antagonist 
(kcal mol−1) 
E2 −10.36 −9.70 −10.11 −9.29 
4 −10.29 −10.38 −10.66 −10.13 
2 −9.82 −9.86 −10.40 −9.71 
11 −9.80 −9.30 −10.18 −10.28 
7 −9.74 −9.37 −10.00 −10.36 
10 −8.82 −9.21 −6.41 −10.08 
13 −8.73 −8.82 −4.82 −9.92 
18 −8.22 −7.66 −7.86 −7.48 
17 −7.37 −7.10 −6.97 −6.83 
16 −7.27 −6.99 −6.92 −6.96 
20 −6.93 −7.20 −7.34 −7.11 
15 −6.85 −6.38 −6.56 −6.77 
14 −6.41 −6.28 −6.43 −6.60 
Compounds identified as having ERα affinity in the fluorescence polarization 
displacement assay are in bold. 
Docking results were rank ordered according to the lowest 
energy pose for binding to the ERα agonist conformation, from the 
cluster with the highest population (Table 2). Identifying the 
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compounds with measurable Kd values from the fluorescence 
polarization displacement assay (shown as bold in Table 2) indicates 
that the docking procedure using Autodock4 was able to separate the 
binding ligands from the non-binding ligands. ER is a unique docking 
target, since the binding site is comprised of a nearly closed 
hydrophobic pocket, flanked by hydrogen bonding groups that could 
provide specificity.31 Care in analyzing docking results is needed due to 
the large binding area in which ligands can potentially bind, and 
symmetry of the pocket. Three examples of reversed binding modes 
that are likely false are shown in Figure 2. 
 
Figure 2 Lowest energy docking poses from clusters where ligands were predicted 
to bind in two modes (A–B). The human ERα estrogen receptor that was used was in 
the agonist conformation (PDB code 1ere; chain A). Panel C shows the predicted 
binding orientation for 18 in ERβ, agonist conformation (PDB code 2jj3; chain A). 
Panel D shows the predicted binding orientation for 18 in ERβ, antagonist 
conformation (PDB code 1l2j; chain A).  
 
Interestingly, while estradiol docked in only one orientation 
when the bound water is present, other compounds were still predicted 
to bind in two orientations (Table 2; Fig. 2), one normal (with the 
phenolic hydroxyl interacting with Arg394/Glu353/Water), and one 
‘reversed,’ where the phenolic hydroxyl interacts with His524. This 
promiscuity in predicted binding mode may be due to symmetry in di-
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Bioorganic & Medicinal Chemistry, Vol. 22, No. 1 (January 1, 2014): pg. 303-310. DOI. This article is © Elsevier and 
permission has been granted for this version to appear in e-Publications@Marquette. Elsevier does not grant permission 
for this article to be further copied/distributed or hosted elsewhere without the express permission from Elsevier. 
12 
 
hydroxyl molecules like 2 (Fig. 2). Curiously, the mono-hydroxyl 4 
also is predicted to bind in a reversed mode (Fig. 2), but with much 
lower affinity relative to the normal mode. This is likely due to the fact 
that 4 has only one hydroxyl group, the phenol, which provides 
significant binding energy via interaction with the 
Arg394/Glu353/water triad. It is also clear that the aliphatic hydroxyl 
interaction with His524 is not essential, since it is absent in 4 and 7, 
and yet both bind with reasonable affinity (IC50 = 160–320 nM). 
Indeed, this observation is consistent with the ability of phenolic 
endocrine disruptors, which contain only one hydroxyl group, to bind 
to ER.32 
The docking of compounds 10 and 13 in the ERβ-agonist 
conformation displayed predicted binding energies that were weaker 
than expected in Table 2. Inspection of the binding site (Fig. S10) 
showed that these ligands experience steric clashes with binding site 
sidechains. Additionally, for structures 10 and 13, the oxygen atom in 
the tetrahydrofuran ring was not positioned near His475 for 10 or (for 
reversed mode binding) near Arg346, Glu305 for 13, to allow for 
hydrogen bond formation. 
Compound 18 is in a unique class, in that it is not based on the 
steroid core, is selective for the β over the α ER isoform, and is 25- 
fold selective for ERβ agonist versus ERβ antagonist activity (Table 1). 
Docking pose predictions (Fig. 2C and D) show that 18 could form two 
hydrogen bonds (one with His475) in the ERβ agonist conformation, 
whereas in the ERβ antagonist conformation, hydrogen bonding is with 
Thr299, rather than His475. A molecular overlay of E2 and 18 (Fig. 
S11) shows the oxygen atoms of the two molecules are well-aligned. 
3. Conclusions 
Human ERα remains an important target for therapeutic 
interventions (cancer; osteoporosis). Estrogen has a key interaction 
between its phenolic hydroxyl and a binding site Arg394/Glu353/water 
triad, along with other important interactions including van der Waals 
interactions with the steroid core, and hydrogen bonding interactions 
between an aliphatic hydroxyl group and His524 (His475 in ERβ). The 
two estradiol hydroxyls are located 11 Å from each other. The studies 
presented herein probe the importance of interactions with the 
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aliphatic hydroxyl and with the steroid core, using a series of novel 
mono- and di-hydroxyl compounds (Schemes 1 and and22). 
The estrogen analog with highest measured affinity in the 
fluorescence polarization displacement assay(IC50 = 32 nM) and 
second highest predicted affinity is the di-hydroxyl steroid 2, which 
has a single point of unsaturation in the D-ring, and (relative to 
estradiol) has its aliphatic hydroxyl extended by one methylene group. 
Nonetheless, this gives an O–O distance essentially equivalent to that 
for estradiol. Di-hydroxyl steroid 2 behaves as an ERα agonist, and 
has no selectivity for α versus β ER isoforms. Indeed, 2 is a potent ERβ 
agonist and antagonist. In contrast, 18 binds weakly to ERα, yet has 
on O–O distance (11.1 Å) that is similar to 2. Of particular interest is 
the fact that 18 has the expected interaction with His475 in the ERβ 
agonist docking, whereas in the ERβ antagonist docking this aliphatic 
hydroxyl group is predicted to interact instead with Thr299 (Fig. 2). 
This could explain why 18 is so selective (25-fold) as an ERβ agonist, 
versus as an antagonist (Table 1). Most of the other compounds from 
Scheme 2 that lacked the steroid core did not bind to ERα, even 
though they possessed the phenolic hydroxyl. Compounds (4, 13, 2), 
which possessed ERα agonist activities, were also ERβ agonists; but, 
not ERβ antagonists. And, these compounds were more selective for 
ERβ over ERα. 
In summary, several compounds have been identified that are 
potent ERα agonists, and also behave as ERβ agonists and antagonists 
(Table 1). The most potent is the dihydroxyl steroid 2. Also, the non-
steroid dihydroxyl compound 18 is 1000-fold more selective for ERβ 
over ERα, and appears to adopt a different binding mode in these two 
targets (Fig. 2). 
4. Experimental 
4.1. General methods 
The β-estradiol (min 98%) and fluorescein (FITC) were 
purchased from Sigma. The α-ER and α-ER screening buffer were from 
Invitrogen. The FITC-estradiol linked tracer used in the experiments 
was synthesized by as described previously. (1) DMSO-d6 was 
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purchased from Cambridge Isotopes. The 96-well plates used were 
black, polystyrene, NBS (non-binding surface), flat-bottom plates 
obtained from Corning. A PolarStar Galaxy fluorescent plate reader 
was used and controlled with FLUOStar Galaxy software (version 4.30-
0). Estrone benzyl ether23 and compounds 3,25 5,26 8,26 and 1728 were 
prepared by the literature procedures. 
4.2. Estrogen analog synthesis 
4.2.1. 3-Hydroxyestra-1,3,5(10),16-tetraene-17-methanol (2)  
To a solution of methyl triphenylphosphonium bromide (589 mg, 
1.65 mmol) in THF (10 mL) at −40 °C under N2, was added a solution 
of n-butyl lithium (0.66 mL, 2.5 M in hexanes, 1.7 mmol). The ylide 
solution was warmed to room temperature and a solution of estrone 
benzyl ether (200 mg, 0.556 mmol) in THF (7 mL) was added. The 
mixture was stirred for 12 h, and then heated at reflux for 5 h. The 
solution was cooled, and concentrated, and the residue was purified by 
column chromatography (SiO2, hexanes–ethyl acetate = 4:1) to afford 
the exocyclic methylene product (168 mg, 84%) as a colorless solid. 
This product was used in the next step without further 
characterization. To a solution of the olefin (100 mg, 0.279 mmol) in 
dichloromethane (6 mL) at 0 °C, was added solid m-
chloroperoxybenzoic acid (57.5 mg, 0.333 mmol). The reaction 
mixture was 4 h, and then quenched with aqueous NaHCO3. The 
mixture was extracted several times with dichloromethane, dried and 
concentrated to afford the epoxide 1 (90 mg, 86%) as a colorless oil, 
which was used in the next step without further purification. To a 
solution of the epoxide (50 mg, 0.13 mmol) in hexanes (1 mL) and 
toluene (0.5 mL) was added HMPA (1 drop). The mixture was cooled to 
−78 °C, and then a solution of lithium diisopropylamine in hexanes 
(0.73 mmol) was added. The solution was warmed to room 
temperature and stirred for 10 h. The mixture was quenched with 
saturated aqueous NH4Cl, and the mixture extracted several times with 
ether. The combined extracts were dried (MgSO4) and concentrated, 
and the residue was purified by column chromatography (SiO2, 
hexanes–ethyl acetate = 3:2) to afford a colorless oil (29 mg, 58%) 
which was used without further characterization. To liquid ammonia 
(ca. 10 mL), at −78 °C was added lithium metal (24 mg, 3.5 mmol), 
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followed by t-butyl alcohol (0.05 mL). To this solution was added a 
solution of the allylic alcohol (20 mg, 0.053 mmol) in THF (1 mL). The 
reaction mixture was stirred at −78 °C for 15 min, and then quenched 
with NH4Cl, and diluted with ether. The mixture was warmed to room 
temperature, and water (10 mL) was added. The mixture was 
extracted several times with ether followed by extraction with 
dichloromethane. The combined extracts were dried (MgSO4), 
concentrated and the residue was purified by column chromatography 
(SiO2, hexanes–ethyl acetate = 3:2) to afford 2 (9.0 mg, 60%) as a 
colorless solid. Mp 192–194 °C; 1H NMR (CDCl3, 400 MHz) δ 7.15 (d, J 
= 8.4 Hz, 1H), 6.64 (dd, J = 2.8, 8.4 Hz, 1H), 6.58 (d, J = 2.8 Hz, 
1H), 5.65 (dd, J = 1.2, 2.8 Hz, 1H), 4.80 (br s, OH), 4.32–4.25 (m, 
2H), 2.95–2.80 (m, 2H), 2.40–1.70 (m, 11 H), 0.87 (s, 3H); 13C NMR 
(CDCl3, 100 MHz) δ 155.2, 153.5, 138.5, 133.1, 126.4, 124.3, 126.4, 
124.3, 115.5, 112.8, 60.4, 56.8, 46.4, 44.6, 37.4, 34.8, 31.1, 29.7, 
27.9, 26.6, 16.5. 
4.2.2. n-Propyl 3-hydroxyestra-1,3,5(10)-triene-17-carboxylate 
(4)  
To a solution of 3 (177 mg, 0.411 mmol) in ethanol (10 mL) 
was added an aqueous slurry of Raney-Ni (60%, 0.6 mL). The reaction 
mixture was stirred under a H2 gas (balloon pressure) for 24 h, after 
which the mixture was filtered through a bed of filter-aid. The filter 
bed was washed several times with ethyl acetate, and the filtrate was 
concentrated under reduced pressure to afford 4 as a colorless solid 
(129 mg, 92%): mp 151.5–153 °C, [α]20D +69.5 (c 0.388, CHCl3); 1H 
NMR (CDCl3, 300 MHz) δ 7.17 (d, J = 8.4 Hz, 1H), 6.64 (dd, J = 2.8, 
8.5 Hz, 1H), 6.57 (d, J = 2.7 Hz, 1H), 4.55 (br s, OH), 4.10 (dt, J = 
10.8, 6.7 Hz, 1H), 4.02 (dt, J = 10.8, 6.7 Hz, 1H), 2.90–2.80 (m, 2H), 
2.44 (t, J = 9.3 Hz, 1H), 2.35–2.15 (m, 3H), 1.90–1.75 (m, 3H), 1.68 
(sextet, J = 7.2 Hz, 2H), 1.55–1.30 (m, 7H), 0.98 (t, J = 7.3 Hz, 3H), 
0.71 (s, 3H); 13C NMR (CDCl3, 75 MHz) δ 174.5, 153.5, 138.4, 132.8, 
126.7, 115.4, 112.8, 66.0, 55.6, 55.1, 44.3, 43.9, 39.0, 38.6, 29.8, 
27.8, 26.7, 24.3, 23.7, 22.3, 13.7, 10.9. Anal. Calcd for 
C22H30O3·1/2H2O: C, 75.18; H 8.89. Found: C, 75.36; H, 8.28. 
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4.2.3. (20S) 3-(Phenylmethoxy)-19,24-dinorchola-1,3,5(10),16-
tetraene (6)  
To a solution of 5 (0.20 g, 0.50 mmol) in benzene (10 mL) in a 
Schlenk flask was added Rh(PPh3)3Cl (40 mg, 0.043 mmol). The 
reaction mixture was cooled with a dry ice–acetone bath, evacuated 
under high vacuum, and the system refilled to 1 atm with H2 gas. The 
mixture was stirred for 7 h at room temperature, and then the solvent 
was evaporated. The residue was extracted several times with ether, 
filtered, and concentrated. The residue was purified by column 
chromatography (SiO2, hexanes–CH2Cl2 = 10:1) to afford 6 (138 mg, 
69%) as a colorless solid. Mp 82–83.5 °C, [α]20D +67 (c 0.74, 
acetone); 1H NMR (CDCl3, 300 MHz) δ 7.46–7.30 (m, 5H), 7.20 (d, J = 
8.4 Hz, 1H), 6.78 (br d, J = 8.4 Hz, 1H), 6.74 (br s, 1H), 5.35 (br s, 
1H), 5.04 (s, 2H), 2.94–2.84 (m, 2H), 2.40–2.08 (m, 4H), 2.00–1.87 
(m, 3H), 1.65–1.28 (m, 7H), 1.09 (d, J = 6.6 Hz, 3H), 0.89 (t, J = 7.3 
Hz, 3H), 0.83 (s, 3H); 13C NMR (CDCl3, 75 MHz) δ 160.2, 155.9, 
137.6, 136.7, 132.9, 128.0, 127.3, 127.0, 125.6, 120.4, 114.4, 111.8, 
70.0, 56.4, 47.8, 44.7, 37.8, 35.4, 33.6, 31.3, 30.3, 30.2, 28.2, 27.0, 
21.3, 17.1, 12.4. Anal. Calcd for C29H36O: C, 86.95; H, 9.06. Found: C, 
86.99; H, 9.12. 
4.2.4. (20S) 3-Hydroxy-19,24-dinorchola-1,3,5(10),16-tetraene 
(7)  
Cleavage of the benzyl ether 6 (73 mg, 0.18 mmol) with sodium 
metal in n-butanol was carried out in a fashion similar to the cleavage 
of 8. Purification of the residue by column chromatography (SiO2, 
hexanes–ethyl acetate gradient = 5:1) gave unreacted starting 
material (17 mg) followed by 7 (46 mg, 81%) as a colorless solid. Mp 
92–95 °C, [α]20D +86.3 (c 0.32, acetone); 1H NMR (acetone-d6) δ 
7.05 (d, J = 8.4 Hz, 1H), 6.56 (dd, J = 2.1, 8.4 Hz, 1H), 6.51 (d, J = 
2.1 Hz, 1H), 5.35 (br s, 1H), 2.82–2.73 (m, 2H), 2.37–2.28 (m, 1H), 
2.22–2.05 (m, 2H), 1.97–1.85 (m, 4H), 1.60–1.26 (m, 8H), 1.07 (d, J 
= 7.2 Hz, 3H), 0.87 (t, J = 7.5 Hz, 3H), 0.82 (s, 3H); 13C NMR 
(acetone-d6) δ 162.5, 156.7, 139.3, 133.2, 127.7, 122.7, 117.1, 
114.7, 58.8, 50.0, 47.1, 40.4, 37.7, 35.8, 33.4, 32.5, 32.2, 30.6, 
29.3, 23.2, 19.0, 14.1. Anal. Calcd for C22H30O·1/6H2O: C, 84.28; H, 
9.75. Found: C, 84.28; H, 9.82. 
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4.2.5. (20S) 3-Hydroxy-19,24-Dinorchola-1,3,5(10),16-tetraen-
23-ol (11)  
To a solution of 8 (394 mg, 0.947 mmol) in n-butanol (20 mL), 
at 70 °C, was added sodium metal (0.87 g, 38 mmol) in small pieces. 
After all of the sodium had reacted, the reaction mixture was cooled to 
room temperature and quenched with water, followed by saturated 
aqueous NH4Cl. The reaction mixture was extracted several times with 
ether, the combined extracts were dried (MgSO4) and concentrated. 
The residue was purified by column chromatography (SiO2, hexanes–
ethyl acetate gradient = 4:1 to 2:1) to afford unreacted starting 
material (91 mg) followed by 11 (150 mg, 49%) as a colorless solid. 
Mp 174.5–176 °C, [α]20D +77.5 (c 1.50, acetone); 1H NMR (acetone-
d6) δ 8.15 (s, phenol OH), 7.04 (d, J = 8.4 Hz, 1H), 6.56 (dd, J = 2.7, 
8.4 Hz, 1H), 6.51 (d, J = 2.7 Hz, 1H), 5.38 (br s, 1H), 3.64–3.52 (m, 
3H), 2.84–2.74 (m, 2H), 2.42–2.28 (m, 2H), 2.20–2.08 (m, 1H), 
1.96–1.70 (m, 4H), 1.60–1.30 (m, 7H), 1.10 (d, J = 7.2 Hz, 3H), 0.82 
(s, 3H); 13C NMR (acetone-d6) δ 162.8, 156.6, 139.2, 133.0, 127.6, 
122.6, 117.0, 114.6, 61.4, 58.7, 49.9, 47.0, 43.0, 40.3, 37.5, 33.2, 
32.0, 30.9, 30.5, 29.2, 23.7, 19.0. Anal. Calcd for C22H30O2: C, 80.94; 
H, 9.26. Found: C, 80.67; H, 9.32. 
4.2.6. 17,23-Epoxy-3-(phenylmethoxy)-19,24-dinorchola-
1,3,5(10)-triene (9)  
To a solution of 8 (56 mg, 0.14 mmol) in CHCl3 (2 mL) was 
added a drop of concentrated HCl. The mixture was allowed to stand 
stirred for 24 h at room temperature, and then passed through a short 
column of silica gel using hexanes–ethyl acetate as eluent. 
Concentration of the eluent gave 9 (50 mg, 89%) as a colorless oil. 
[α]20D +36 (c 1.0, CH2Cl2); 1H NMR (CDCl3, 300 MHz) δ 7.46–7.28 
(m, 5H), 7.22 (d, J = 8.4 Hz, 1H), 6.87 (dd, J = 2.7, 8.4 Hz, 1H), 6.73 
(d, J = 2.7 Hz, 1H), 5.04 (s, 2H), 3.87 (dt, J = 4.5, 7.8 Hz, 1), 3.62 
(dt, J = 6.4, 7.8 Hz, 1H), 2.92–2.82 (m, 2H), 2.38– 1.20 (m, 16H), 
1.10 (d, J = 6.9 Hz, 3H), 0.74 (s, 3H); 13C NMR (CDCl3, 75 MHz) δ 
155.8, 137.6, 136.7, 132.8, 128.2, 127.3, 126.9, 125.8, 114.4, 111.8, 
95.5, 70.0, 66.0, 50.0, 48.2, 44.0, 39.3, 36.9, 35.1, 31.3, 31.0, 30.3, 
28.1, 26.6, 23.6, 19.0, 15.8. Anal. Calcd for C29H36O2: C, 83.61; H 
8.71. Found: C, 83.35; H, 8.75. 
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4.2.7. 17,23-Epoxy-3-hydroxy-19,24-dinorchola-1,3,5(10)-
triene (10)  
To a solution of 9 (48.9 mg, 0.118 mmol) in methanol/CHCl3 
(1:100, 6 mL) was added 10% Pd on carbon (5.6 mg). The mixture 
was stirred under H2 (ca. 46 psi) in a Paar hydrogenation apparatus for 
3 h. The catalyst was removed by filtration through filter-aid and the 
filter bed was washed with copious CH2Cl2 and the combined filtrates 
were concentrated. The residue was purified by chromatography (SiO2, 
hexanes–ethyl acetate = 3:1) to afford 10 as a colorless solid (37.8 
mg, 99%). Mp 172–174 °C; 1H NMR (CDCl3, 300 MHz) δ 7.15 (d, J = 
8.4 Hz, 1H), 6.62 (dd, J = 2.7, 8.4 Hz, 1H), 6.55 (d, J = 2.7 Hz, 1H), 
3.87 (dt, J = 4.5, 7.8 Hz, 1H), 3.60 (dt, J = 6.3, 8.1 Hz, 1H), 2.85–
2.75 (m, 2H), 2.35–1.20 (m, 16H), 1.07 (d, J = 6.9 Hz, 3H), 0.70 (s, 
3H); 13C NMR (CDCl3, 75 MHz) δ 153.3, 138.6, 133.2, 126.6, 115.4, 
112.7, 96.0, 66.1, 50.0, 48.2, 43.9, 39.3, 36.8, 35.0, 31.2, 30.8, 
30.0, 27.9, 26.4, 23.4, 18.8, 15.6. Anal. Calcd for C22H30O2·1/4H2O: C, 
79.83; H 9.29. Found: C, 80.12; H, 9.33. 
4.2.8. (20S) 3-Hydroxy-19,24-dinorchola-1,3,5(10),16-tetraen-
23-al (12)  
To a solution of 11 (100 mg, 0.296 mmol) in THF (4 mL) was 
added a solution of ethyl magnesium bromide in THF (0.67 mL, 1.0 M, 
0.67 mmol). The solution was stirred at room temperature for 15 min, 
and then solid 1,1′-(azodicarbonyl)dipiperidine (0.17 g, 0.67 mmol) 
was added. The reaction mixture was stirred for 1 h, and then 
quenched with saturated aqueous NH4Cl and extracted several times 
with ether. The combined ethereal extracts were dried (MgSO4), 
concentrated and the residue was purified by column chromatography 
(SiO2, hexanes–ethyl acetate = 5:1) to afford 12 as a colorless solid 
(66 mg, 66%). Mp 168.5–171 °C, [α]20D +78 (c 0.80, acetone); 1H 
NMR (acetone-d6, 300 MHz) δ 9.66 (t, J = 2.1 Hz, 1H), 7.06 (d, J = 
8.4 Hz, 1H), 6.57 (dd, J = 2.5, 8.4 Hz, 1H), 6.51 (d, J = 2.5 Hz, 1H), 
5.46 (br s, 1H), 2.90–2.75 (m, 4H), 2.62 (ddd, J = 1.8, 5.7, 16.2 Hz, 
1H), 2.44–2.30 (m, 2H), 2.26–2.10 (m, 2H), 1.98–1.86 (m, 3H), 
1.60–1.34 (m, 5H), 1.16 (d, J = 7.2 Hz, 3H), 0.88 (s, 3H); 13C NMR 
(acetone-d6, 75 MHz) δ 203.2, 161.4, 156.8, 139.5, 133.3, 127.9, 
124.6, 117.2, 114.8, 59.2, 53.1, 50.2, 47.2, 40.5, 37.7, 33.6, 32.3, 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Bioorganic & Medicinal Chemistry, Vol. 22, No. 1 (January 1, 2014): pg. 303-310. DOI. This article is © Elsevier and 
permission has been granted for this version to appear in e-Publications@Marquette. Elsevier does not grant permission 
for this article to be further copied/distributed or hosted elsewhere without the express permission from Elsevier. 
19 
 
30.7, 29.7, 29.4, 23.8, 19.3. Anal. Calcd for C22H28O2: C, 81.44; H, 
8.70. Found: C, 81.21; H, 8.54. 
4.2.9. 17,23-Epoxy-3-hydroxy-19-norchola-1,3,5(10)-triene 
(13)  
To a solution of 12 (45.9 mg, 0.142 mmol) in THF (7 mL) at 
0 °C was added a solution of methyl magnesium bromide in ether 
(0.10 mL, 3.0 M, 0.30 mmol). The reaction mixture was stirred for 3 h, 
and then quenched with saturated aqueous NH4Cl (15 mL). The 
mixture was extracted several times with CH2Cl2 and the combined 
extracts were dried (MgSO4) and concentrated. The residue was 
purified by chromatography (SiO2, hexanes–ethyl acetate = 5:1) to 
afford 13 as a colorless solid (44 mg, 92%). Analysis of the product by 
1H NMR spectroscopy indicated this to be a 1:1 mixture of 
diastereomers. Mp 248–251 °C, 1H NMR (CDCl3, 300 MHz) δ 7.15 (d, J 
= 8.4 Hz, 1H), 6.62 (dd, J = 2.7, 8.4 Hz, 1H), 6.56 (d, J = 2.7 Hz, 
1H), 4.18–4.07 (m, 1H), 3.85–3.74 (m, 1H), 2.85–2.75 (m, 2H), 
2.35–1.20 (m, 15H), 1.23 & 1.20 (2 × d, J = 5.7 Hz, 3H total), 1.07 & 
1.05 (2 × d, J = 6.9 Hz, 3H), 0.72 & 0.66 (2 × s, 3H total); 13C NMR 
(CDCl3, 75 MHz) δ 153.3, 138.6, 133.2, 126.6, 115.4, 112.7, 97.1 
[95.8], 73.6 [71.3], 49.85 [49.80], 48.8, 47.1, 45.4, 43.9 [43.8], 
43.5, 39.3 [39.2], 36.2, 34.5, 32.3, 31.2 [30.9], 30.6 [30.1], 27.8, 
26.5 [26.4], 23.5 [23.4], 21.6, 19.2 [18.9], 16.3 [14.9]. Anal. Calcd 
for C23H32O2·1/2H 2O: C, 79.04; H, 9.52. Found: C, 79.34; H, 9.57. 
4.2.10. cis- and trans-4-(4′-Hydroxycyclohexyl)phenol (14)  
To a solution of 4-(4′-hydroxyphenyl)cyclohexanone (50 mg, 
0.26 mmol) in methanol (1 mL) was added NaBH4 (15 mg, 4.0 mmol). 
The reaction mixture was stirred for 30 min, and then diluted with 
water. The mixture was extracted several times with ethyl acetate and 
the combined extracts were concentrated and purified by column 
chromatography (SiO2, hexanes–ethyl acetate = 2:1) to afford cis-14 
(5.0 mg, 10%) followed by trans-15 (43 mg, 86%) both as colorless 
solids. Cis-14: 1H NMR (CD3OD, 400 MHz) δ 7.04–6.69 (AA′BB′, JAB = 
8.8 Hz, 4H), 4.02 (narrow t, J = 2.8 Hz, 1H), 2.50–2.40 (m, 1H), 
1.91–1.79 (m, 4H), 1.69–1.52 (m, 4H); 13C NMR (CD3OD, 75 MHz) δ 
156.5, 140.1, 128.8, 116.1, 66.5, 44.5, 34.0, 29.4. Trans-15: 1H NMR 
(CD3OD, 400 MHz) δ 7.01–6.68 (AA′BB′, JAB = 8.4 Hz, 4H), 3.58 (tt, J 
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= 4.4, 10.6 Hz, 1H), 2.39 (tt, J = 3.5, 11.8 Hz, 1H), 2.06–1.99 (m, 
2H), 1.87–1.79 (m, 2H), 1.56–1.33 (m, 4H). 
4.2.11. 4-(4-Hydroxyphenyl)-cyclohexanone oxime (16)  
To a solution of 4-(4′-hydroxyphenyl)cyclohexanone (50 mg, 
0.26 mmol), hydroxylamine hydrochloride (36.6 mg, 0.526 mmol) in 
ethanol (5 mL) was added Amberlyst (56 mg). After stirring for 2 h, 
the mixture was filtered, and the filtrate concentrated. The residue 
was partitioned between water and ethyl acetate, and the organic 
layer was concentrated and dried to give (±)-16 (44 mg, 82%) as a 
colorless solid. Mp 172–175 °C. 1H NMR (CD3OD, 400 MHz) δ 7.03–
6.69 (AA′BB′, JAB = 8.8 Hz, 4H), 4.02 (narrow t, J = 2.8 Hz, 1H), 2.0–
2.40 (m, 1H), 1.91–1.79 (m, 4H), 1.69–1.52 (m, 4H); 13C NMR 
(CD3OD, 75 MHz) δ 161.0, 156.8, 138.4, 128.7, 116.3, 44.3, 36.0, 
34.7, 33.0, 25.2. HRMS (ESI): m/z calcd for C12H15NO2+Na+ [M+Na]+ 
228.0995, found 228.0997. 
4.2.12. cis-1-Hydroxymethyl-4-(4′-hydroxyphenyl)-cycloheptane 
(18)  
To a solution of (±)-17 (75 mg, 0.35 mmol) in methanol (15 
mL) in a heavy walled reaction vessel, was added a catalytic amount 
of 20% Pd/C. The mixture was stirred under H2 pressure (45 psi) for 
75 min and then the reaction mixture was filtered through the pad of 
celite. The filtrate was concentrated and the residue was purified by 
column chromatography (SiO2, hexanes–ethyl acetate = 65:35) to 
afford (±)-18 (38 mg, 50%) as a colorless solid. Mp 60–61 °C; 1H 
NMR (CDCl3, 300 MHz) δ 7.06 and 6.75 (AA′BB′, JAB = 9.0 Hz, 4H), 
3.48 (d, J = 6.3 Hz, 1H), 2.59–2.58 (m, 1H), 1.95– 1.08 (m, 13H); 13C 
NMR (CD3OD, 75 MHz) δ 127.9, 115.3, 68.6, 46.1, 41.4, 38.8, 33.1, 
31.6, 28.5, 27.5. HRMS (ESI): m/z calcd for C14- H20O2+Na+ [M+Na]+ 
243.1356, found 243.1356. 
4.2.13. 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-2-furanmethanol 
(20)  
A solution of methyl 5-bromo-2-furanoate (1.03 g, 5.02 mmol), 
4-acetoxystyrene (0.97 g, 6.0 mmol), palladium acetate (0.01 g, 0.05 
mmol), tri-o-tolylphosphine (0.03 g, 0.2 mmol), and triethylamine (3 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Bioorganic & Medicinal Chemistry, Vol. 22, No. 1 (January 1, 2014): pg. 303-310. DOI. This article is © Elsevier and 
permission has been granted for this version to appear in e-Publications@Marquette. Elsevier does not grant permission 
for this article to be further copied/distributed or hosted elsewhere without the express permission from Elsevier. 
21 
 
mL) was heated under nitrogen in a sealed heavy-walled Pyrex tube at 
100 °C for 24 h. The reaction mixture was cooled, diluted with water 
and dichloromethane. The dichloromethane layer was separated, 
washed with water, and dried (MgSO4), and the residue was purified 
by column chromatography (SiO2, hexanes–ethyl acetate = 4:1) to 
afford 19 (350 mg, 24%), a pale yellow solid. Mp 110.5–112 °C; 1H 
NMR (CDCl3, 300 MHz) δ 7.51 (d, J = 8.1, 2H), 7.27 (d, J = 16.5 Hz, 
1H), 7.20 (d, J = 3.6 Hz, 1H), 7.10 (d, J = 8.1 Hz, 2H), 6.86 (d, J = 
16.5 Hz, 1H), 6.45 (d, J = 3.6 Hz, 1H), 3.92 (s, 3H, OMe), 2.32 (s, 3H, 
OAc). This product was used in the next step without further 
characterization. To a solution of diester (50 mg, 0.17 mmol) in 
anhydrous ether (1 mL) at 0 °C, was slowly added a solution of lithium 
aluminium hydride (0.52 mL, 1.0 M in THF, 0.52 mmol). Solution was 
stirred for 3 h at 0 °C and then saturated aqueous sodium bicarbonate 
(2 mL) was added follow by dilute sodium hydroxide. The mixture was 
warmed to room temperature, extracted several times with ethyl 
acetate. The combined extracts were dried (MgSO4), concentrated and 
the residue was purified by column chromatography (SiO2, hexanes–
ethyl acetate = 1:1) gave 20 (28 mg, 74%) as a colorless solid. Mp 
129–131 °C; 1H NMR (acetone- d6, 300 MHz) δ 8.59 (br s, 1H), 7.40 
(d, J = 9.0 Hz, 2H), 6.97– 6.79 (m, 4H), 6.30 (s, 2H), 4.57 (br s, 2H), 
3.05 (br s, 1H); 13C NMR (acetone-d6, 75 MHz) δ 158.2, 155.9, 154.1, 
129.7, 128.6, 127.4, 116.5, 114.9, 109.9, 109.4, 57.4. HRMS (ESI): 
m/z calcd for C13H12O3+Na+ [M+Na]+ 239.0679, found 239.0681. 
4.3. Fluorescence polarization 
The assay was developed based on a commercially available kit 
from Invitrogen.15 Assays were run on a BMG POLARstar Galaxy reader 
with acquisition parameters as follows: 200 flashes, positioning delay 
1.0 s, K factor ≤ 1.1 and ≥ 0.9, excitation filter of 485 ± 5 nm and 
emission filter of 520 ± 15 nm. For the IC50 determinations the [ER-α] 
was 30 nM and the [FITC-estradiol tracer] ([Tr]) was 10 nM. Sample 
volume was 150 μL. For each experiment the polarization was 
calibrated with a sample of FITC set at 20 mP. All proper blanks were 
used, including water for the FITC samples and blank samples 
containing only 30 nM ERα protein for the remaining data points. All 
protein samples contained 1% DMSO-d6, the maximum amount 
tolerated as stated by the supplier of the ERα protein, Invitrogen, to 
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ensure the solubility of all hydrophobic compounds investigated. The 
Kd of the FITC-tagged estradiol for ER-α was determined by non-linear 
least squares fitting of the titration curve data to the following 
equation (where Tro is the F-E2 tracer):  
ΔFP= 
FPmax 
(Kd+[Tr0]+[ERα]) 
2[Tr0] 
−{(Kd+[Tr0]+[ERα])2−4[Tr0]}+[ERα] 
  
4.4. Cell-based ERα and ERβ assays 
ERα and ERβ assay kits for cell-based assays (Indigo 
Biosciences) allowed for investigation into the functional activity (i.e., 
agonist and/or antagonist) of the ligands identified to bind based on 
the initial fluorescence polarization displacement assay. Briefly, the 
cells contained a luciferase reporter gene that was functionally linked 
to either the ERα or ERβ-responsive promoter. By quantifying the 
luciferase expression via luminescence, the change in ER activity could 
be quantified. 1–2 mM stocks of the ligands were prepared in DMSO-d6 
and diluted to final concentrations ranging from 3.2 nM to 2 μM, using 
the Compound Screening Medium provided in the kit. For the agonist 
assay, the cells were prepared by warming to 37 °C, plated, then the 
chemicals added. For the antagonist assay, the cells were prepared as 
above with the addition of E2 (for ERα 3.2 nM was added, 
approximating an IC75; and, for ERβ 160 pM was added, approximating 
an IC80). The cells were then plated, and the chemicals added. All 
plates were incubated in a cell culture incubator at 37 °C and 5% CO2 
for 22 h. Each assay was performed in duplicate. Luminescence was 
characterized after removal of the incubating media and introduction 
of the Detection Substrate using a Molecular Devices SpectraMax M5 
microplate reader. Data was fitted using GraphPad Prism and fit to the 
dose-response (four paramter) equation as follows. 
y= 
bottom−(top−bottom) 
(1+10(logIC50−x)Hillslope) 
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4.5. Molecular docking 
Ligand structures were drawn in PC Spartan Plus (Wavefunction) 
and three dimensional (3D) conformation was then optimized using 
semiempirical Austin Model 1 (AM1) calculations. Since compound 13 
was afforded as a pair of diastereomers both were modeled and 
docked. The AM1 calculations provided geometries and bond distances 
for subsequent docking. AutoDock Tools (ADT) was used prepare the 
ligand files according to AutoDock requirements and assign Gasteiger 
charges. 
The ERα receptor for agonist (pdb code 1ere)4 and antagonist 
(pdb code 1err)32 conformations were prepared for docking 
calculations using the ‘A’ chain. The ERβ receptor for agonist (pdb code 
2jj3)33 and antagonist (pdb code 1l2j)34 conformations were prepared 
for docking calculations using the ‘A’ chain. ADT was used to further 
prepare the ER receptor files by adding hydrogen atoms and adding 
partial charges to each atom of the protein. The grid box was centered 
on the co-crystallized ligand, drawn to a box to incorporate amino 
acids Arg394, Glu353, and His524 for ERα and Arg346, Glu305, and 
His475 for ERβ, then the estradiol ligand was removed.35 AutoDock (v. 
4.2) calculations were performed with default parameters, except with 
100 genetic algorithmic runs and 2,500,000 evaluations per run.35–39 
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Footnotes 
A. Supplementary data 
Supplementary data associated with this article can be found, in the 
online version, at http://dx.doi.org/10.1016/j.bmc.2013.11.024. 
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Supplementary Material 1 
 
 
Supplementary Figure S1. Cell-based ERα assay data including regression for 
ligands that showed agonist activity. 
 
 
Supplementary Figure S2. Cell-based ERα agonist assay data for chemicals without 
sufficient quality data to determine activity. 
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Supplementary Figure S3. Cell-based ERα antagonist assay data for chemicals 
without sufficient quality data to determine activity. 
 
 
Supplementary Figure S4. Cell-based ERβ agonist assay data. for ligands that 
showed antagonist activity 
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Supplementary Figure S5. Cell-based ERβ assay data for chemicals that showed 
antagonist activity. 
 
Supplementary Figure S6. Cell-based ERβ assay data for chemicals that did not 
display antagonist activity. 
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Supplementary Figure S7. Lowest energy docking poses for the ERα-binding 
compounds identified using fluorescence polarization.  PDB file 1ere, chain A was used 
as the receptor to investigate the predicted affinity for binding in the ERα agonist 
conformation.  Note: E2 is estradiol and provided for comparison. 
 
Supplementary Figure S8. Lowest energy docking poses for the ERα-binding 
compounds identified using fluorescence polarization.  PDB file 1ere, chain A was used 
as the receptor to investigate the predicted affinity for binding in the ERα agonist 
conformation.  Note: chemical 13 was docked using both enantiomers from the 
racemic mixture. 
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Supplementary Figure S9. Estradiol docked into PDB file 1ere, chain A with removal 
of all water molecules.  Black is the binding mode associated with the crystal structure 
(normal).  Gray is a 180° rotation of the estradiol (reversed). 
 
 
Supplementary Figure S10. ERβ agonist conformation (purple) with cocrystalized 
ligand (green) and docking pose predictions of 10 (blue) and 13 (yellow). 
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Supplementary Figure S11. Overlay of estradiol (black) and 18 (yellow). 
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Supplementary Table S1.  Docking results for the agonist conformation of ER in 
the absence of all water molecules.   
 
Compound 
Number of 
Clusters 
(2.0Å rmsd) 
Lowest 
Energy 
Cluster 
Population 
Calculated 
Binding 
Energy (kcal 
mol-1) 
Mode 
estradiol 2 69 -10.74 reversed 
estradiol  31 -10.72 normal 
4 2 64 -11.09 reversed 
4  36 -10.71 normal 
2 1 100 -10.98 reversed 
7 2 56 -9.93 reversed 
7  44 -9.79 normal 
11 3 69 -10.35 reversed 
11  29 -9.28 normal 
11  2 -9.16 reversed 
10 2 96 -9.48 reversed 
10  4 -9.08 normal 
13a 1 100 -7.44 normal 
13b 1 100 -9.13 reversed 
17 3 22 -7.27 reversed 
17  76 -7.21 reversed 
17  2 -7.12 normal 
20 1 100 -7.57 reversed 
18 2 85 -7.42 reversed 
18  15 -7.34 normal 
14 2 97 -6.71 normal 
14  3 -6.39 reversed 
15 2 73 -6.85 normal 
15  27 -6.77 reversed 
16 3 71 -7.42 reversed 
16  28 -7.33 normal 
16  1 -7.17 normal 
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Supplementary Table S2.  Docking results for the agonist conformation of ER in 
the presence of a single water molecule near Arg294 and Glu353 as observed in the 
crystal structure.  Chemicals 20 and 14 were not predicted to bind similarly to the 
normal or reversed modes as otherwise noted. 
 
Compound 
Number of 
Clusters 
(2.0Å rmsd) 
Lowest 
Energy 
Cluster 
Population 
Calculated 
Binding 
Energy 
(kcal mol-
1) 
Mode 
estradiol 1 100 -10.36 normal 
4 2 97 -10.29 normal 
2 2 42 -10.16 reversed 
2 2 58 -9.82 normal 
11 1 100 -9.80 normal 
7 1 100 -9.74 normal 
10 1 100 -8.82 normal 
13b 1 100 -8.73 normal 
13a 1 100 -8.39 normal 
4 2 3 -7.73 reversed 
18 2 72 -7.56 reversed 
18 2 28 -7.46 normal 
17 2 13 -7.46 reversed 
17 2 87 -7.37 normal 
16 2 97 -7.27 normal 
15 2 73 -7.00 reversed 
16 2 3 -6.94 reversed 
20 4 76 -6.93 other 
15 2 27 -6.85 normal 
14 3 79 -6.41 other 
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